D&D Pharmatech (A347850) Stock Overview
Engages in the research and development and manufacturing of pharmaceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A347850 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
D&D Pharmatech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩79,200.00 |
| 52 Week High | ₩113,700.00 |
| 52 Week Low | ₩10,125.00 |
| Beta | 0 |
| 1 Month Change | -23.18% |
| 3 Month Change | 6.13% |
| 1 Year Change | 465.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 767.95% |
Recent News & Updates
Companies Like D&D Pharmatech (KOSDAQ:347850) Are In A Position To Invest In Growth
Dec 13
Is D&D Pharmatech (KOSDAQ:347850) In A Good Position To Deliver On Growth Plans?
Aug 28Shareholder Returns
| A347850 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -12.3% | -0.9% | -0.2% |
| 1Y | 465.7% | 42.7% | 100.6% |
Return vs Industry: A347850 exceeded the KR Biotechs industry which returned 43.9% over the past year.
Return vs Market: A347850 exceeded the KR Market which returned 102.1% over the past year.
Price Volatility
| A347850 volatility | |
|---|---|
| A347850 Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in KR Market | 13.0% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A347850's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A347850's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Seul-ki Lee | www.ddpharmatech.com |
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications.
D&D Pharmatech Inc. Fundamentals Summary
| A347850 fundamental statistics | |
|---|---|
| Market cap | ₩3.45t |
| Earnings (TTM) | -₩34.76b |
| Revenue (TTM) | ₩8.36b |
Is A347850 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A347850 income statement (TTM) | |
|---|---|
| Revenue | ₩8.36b |
| Cost of Revenue | ₩27.03m |
| Gross Profit | ₩8.34b |
| Other Expenses | ₩43.09b |
| Earnings | -₩34.76b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -798.33 |
| Gross Margin | 99.68% |
| Net Profit Margin | -415.59% |
| Debt/Equity Ratio | 0% |
How did A347850 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 04:39 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
D&D Pharmatech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.